Tags

Type your tag names separated by a space and hit enter

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.
Lancet. 1998 Mar 07; 351(9104):709-13.Lct

Abstract

BACKGROUND

The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.

METHODS

320 children who lived in a hyperendemic area for P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.

FINDINGS

25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0.001). Adverse events during the chemosuppression phase did not differ between the groups.

INTERPRETATION

The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.

Authors+Show Affiliations

Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9504515

Citation

Lell, B, et al. "Randomised Placebo-controlled Study of Atovaquone Plus Proguanil for Malaria Prophylaxis in Children." Lancet (London, England), vol. 351, no. 9104, 1998, pp. 709-13.
Lell B, Luckner D, Ndjavé M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998;351(9104):709-13.
Lell, B., Luckner, D., Ndjavé, M., Scott, T., & Kremsner, P. G. (1998). Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet (London, England), 351(9104), 709-13.
Lell B, et al. Randomised Placebo-controlled Study of Atovaquone Plus Proguanil for Malaria Prophylaxis in Children. Lancet. 1998 Mar 7;351(9104):709-13. PubMed PMID: 9504515.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. AU - Lell,B, AU - Luckner,D, AU - Ndjavé,M, AU - Scott,T, AU - Kremsner,P G, PY - 1998/3/21/pubmed PY - 1998/3/21/medline PY - 1998/3/21/entrez KW - Africa KW - Africa South Of The Sahara KW - Age Factors KW - Case Control Studies KW - Child KW - Child Health KW - Demographic Factors KW - Developing Countries KW - Diseases KW - Drugs KW - French Speaking Africa KW - Gabon KW - Health KW - Malaria--prevention and control KW - Middle Africa KW - Parasitic Diseases KW - Population KW - Population Characteristics KW - Research Methodology KW - Research Report KW - Studies KW - Treatment KW - Youth SP - 709 EP - 13 JF - Lancet (London, England) JO - Lancet VL - 351 IS - 9104 N2 - BACKGROUND: The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis. METHODS: 320 children who lived in a hyperendemic area for P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear. FINDINGS: 25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0.001). Adverse events during the chemosuppression phase did not differ between the groups. INTERPRETATION: The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/9504515/Randomised_placebo_controlled_study_of_atovaquone_plus_proguanil_for_malaria_prophylaxis_in_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(97)09222-2 DB - PRIME DP - Unbound Medicine ER -